Press Releases

Nov 12, 2026

Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting

Nov 10, 2026

Ionis to present at upcoming investor conferences

Nov 09, 2026

Ionis reports third quarter 2026 financial results and highlights progress on key programs

Nov 02, 2026

Ionis to hold third quarter 2026 financial results webcast

Oct 23, 2026

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Oct 22, 2026

Ionis ranked #1 on Science’s Top Employers list

Oct 20, 2026

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

Oct 16, 2026

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Sep 23, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Sep 22, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

Sep 04, 2026

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Sep 03, 2026

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Sep 03, 2026

Ionis to present at upcoming investor conferences

Aug 20, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

Jul 29, 2026

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Jul 29, 2026

Ionis reports second quarter 2026 financial results and highlights progress on key programs

Jul 15, 2026

Ionis to hold second quarter 2026 financial results webcast

Jul 14, 2026

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Jul 13, 2026

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Jul 09, 2026

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

Jul 06, 2026

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

Jun 25, 2026

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

Jun 24, 2026

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

Jun 08, 2026

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Jun 04, 2026

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

May 28, 2026

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

May 14, 2026

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

May 04, 2026

Ionis to host 2026 virtual Annual Meeting of Stockholders

May 01, 2026

Ionis to present at upcoming investor conferences

Apr 29, 2026

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Apr 28, 2026

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Apr 21, 2026

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Apr 15, 2026

Ionis to hold first quarter 2026 financial results webcast

Mar 23, 2026

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Mar 09, 2026

Ionis announces changes to Board of Directors

Feb 27, 2026

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Feb 26, 2026

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Feb 25, 2026

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Feb 19, 2026

Ionis to present at upcoming investor conferences

Feb 17, 2026

Ionis updates time for fourth quarter and full year 2025 financial results webcast

Feb 11, 2026

Ionis to hold fourth quarter and full year 2025 financial results webcast

Jan 21, 2026

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Jan 12, 2026

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

Jan 07, 2026

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Jan 06, 2026

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference